Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion type Assertion NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_head.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion evidence source_evidence_literature NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion SIO_000772 25512250 NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion wasDerivedFrom befree-2016 NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion wasGeneratedBy ECO_0000203 NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.